trial
as of 2026-07-01Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
NCTId NCT00790192
at a glance
Phase 3 · Completed
Enrollment 488 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2010-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
488 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-10
Primary completion
2010-07
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Drugs
Indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Medical Director, MDStudy Director
Sites
65 total
Little Rock, United StatesLittle Rock, United StatesCerritos, United StatesCerritos, United StatesCosta Mesa, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesParamount, United StatesPasadena, United StatesPico Rivera, United StatesRiverside, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
488
Phase
PHASE3
Primary Completion Date
2010-07
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
indication
indication
indication
investigator
person